CASP3 and movement disorder: Injection of sitagliptin (5, 10, and 20 mg/kg) with ACR, as well as administration of sitagliptin 10 mg/kg from day 6 with ACR for 11 days, lessened MDA amounts in brain tissue, and receiving vitamin E with ACR, which was as a positive control group, reduced movement disorders, decreased MDA, increased GSH content, reduced TNF-α and caspase-3 levels in cortex tissue compared to the ACR receiving group.